Table 2. Fold changes (suspension/adherent) and p-values of compounds identified from MDA-MB-468 human breast cancer cells.
| Compoundsa | Fold change | p-valueb |
|---|---|---|
| Cer (d18:1/16:0) | 0.33 | 2.07E-03 |
| Cer (d18:1/17:0) | 0.56 | n.s. |
| Cer (d18:1/18:0) | 0.48 | 6.18E-03 |
| PC (14:0/16:0) | 0.68 | 1.64E-06 |
| PC (16:0/16:0) | 1.70 | 1.85E-07 |
| PC (16:0/16:1) | 0.83 | 3.83E-03 |
| PC (16:0/18:1) | 0.98 | n.s. |
| PC (16:1/18:1) | 1.20 | n.s. |
| PC (18:0/22:5) | 1.48 | 4.42E-03 |
| PC (18:1/18:1) | 1.51 | 1.34E-02 |
| PC (18:1/18:2) | 1.69 | 3.17E-03 |
| PC (18:1/20:4) | 1.36 | n.s. |
| PC (18:1/20:5) | 1.76 | 2.46E-02 |
| PE (P-16:0/20:4) | 0.93 | n.s. |
| PE (18:0/18:1) | 0.74 | 1.59E-04 |
| PE (18:0/20:4) | 1.89 | 8.00E-11 |
| PE (18:0/22:5; 18:1/22:4) | 1.45 | 7.47E-06 |
| PE (18:1/18:1) | 0.49 | 9.97E-14 |
| PE (18:1/20:4) | 1.01 | n.s. |
| PG (16:0/18:1) | 0.79 | 1.20E-05 |
| PG (18:0/18:1) | 0.80 | n.s. |
| PG (18:1/18:1) | 0.50 | 8.14E-09 |
| PS (16:0/18:0) | 0.70 | n.s. |
| PS (16:0/18:1; 16:1/18:0) | 0.57 | n.s. |
| PS (16:1/18:1) | 0.47 | n.s. |
| PS (18:0/18:0) | 0.77 | 9.58E-03 |
| PS (18:0/18:1) | 0.60 | 1.62E-03 |
| PS (18:0/20:1) | 1.03 | n.s. |
| PS (18:0/20:3) | 2.44 | 3.45E-09 |
| PS (18:0/20:4) | 3.73 | 4.97E-03 |
| PS (18:0/22:5) | 0.67 | 1.97E-06 |
| PS (18:0/22:6) | 0.97 | n.s. |
| PS (18:1/18:1) | 0.42 | 3.46E-02 |
| PS (18:1/18:2) | 0.78 | n.s. |
| PI (16:0/18:1) | 0.57 | 7.28E-08 |
| PI (16:0/20:4) | 1.41 | 1.63E-07 |
| PI (16:1/18:1) | 0.83 | n.s. |
| PI (18:0/20:3) | 1.29 | 5.07E-07 |
| PI (18:0/20:4) | 1.58 | 2.00E-11 |
| PI (18:1/18:1) | 0.43 | 2.36E-15 |
| PI (18:1/18:2) | 1.12 | 1.07E-02 |
| PI (18:1/20:4) | 0.90 | 2.75E-02 |
aCer, ceramide; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PS, phosphatidylserine; PI, phosphatidylinositol.
bn.s., not statistically significant (p < 0.05).